Table 1 Ongoing and planned clinical trials of inflammasome pathway inhibition in COVID-19
From: Inflammasome activation at the crux of severe COVID-19
Trial | Type, size and inclusion | Intervention and end points |
|---|---|---|
Targeting NLRP3 | ||
Novartis DFV890 (NCT04382053) | Multicentre, randomized, controlled; 143 participants | Administered for 14 days in addition to standard of care; day 15 APACHE II severity or day of discharge |
Olatec Therapeutics Dapansutrile (NCT04540120) | Randomized, double blind, placebo controlled; 80 participants | Initial dose of 8 × 250 mg on first day; 4 × 250-mg capsules for 14 days; proportion of participants with clinical deterioration at day 15, defined as COVID-19-related hospitalization or both worsening shortness of breath and oxygen saturation less than 92% on room air |
Targeting gasdermin D | ||
University of California, San Francisco Disulfiram for COVID-19 (DISCO) trial (NCT04485130) | Randomized, dose escalation, placebo controlled, double blind; 60 participants | 1,000 mg per day for 5 days or 2,000 mg per day for 5 days; plasma levels of IL-1β, IL-6 and other cytokines at 31 days |
ETICA Disulfiram (NCT04594343) | Randomized, double blind, placebo controlled; 200 participants | 500 mg per day for 14 days; plasma IL-18 level at day 7 |
University of Oxford RECOVERY trial Dimethyl fumarate (NCT04381936) | Randomized, open label | 120 mg every 12 hours for 2 days and 240 mg every 12 hours for 8 days; mortality 28 days after randomization |
